Jonas Jarvius has informed Q-linea AB:s (publ) board of directors that he plans to step down as CEO before summer 2024 to take over as CEO of a US based life science company. Three of the major shareholders of Q-linea (69% of the shares) has informed the Board of Directors of its intention to support Jonas Jarvius as a new board member in 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 SEK | -2.75% | -7.42% | -42.70% |
Apr. 26 | Q-Linea AB Receives FDA 510(k) Clearance for the ASTar® System | CI |
Mar. 13 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-42.70% | 23.79M | |
-18.97% | 18.12B | |
-42.48% | 2.87B | |
+22.69% | 1.9B | |
-1.56% | 1.65B | |
+32.98% | 1.34B | |
-17.41% | 957M | |
-22.25% | 896M | |
+10.31% | 841M | |
-26.78% | 612M |
- Stock Market
- Equities
- QLINEA Stock
- News Q-linea AB
- Q-Linea AB Announces Jonas Jarvius to Step Down as CEO Before Summer 2024